Growth Metrics

Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Historic Long-Term Deferred Tax for Moderna (MRNA) over the last 4 years, with Q3 2024 value amounting to $81.0 million.

  • Moderna's Long-Term Deferred Tax changed N/A to $81.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $81.0 million, marking a year-over-year change of. This contributed to the annual value of $81.0 million for FY2023, which is 9175.15% down from last year.
  • Moderna's Long-Term Deferred Tax amounted to $81.0 million in Q3 2024.
  • In the past 5 years, Moderna's Long-Term Deferred Tax ranged from a high of $1.5 billion in Q2 2023 and a low of $50.0 million during Q1 2021
  • For the 4-year period, Moderna's Long-Term Deferred Tax averaged around $485.5 million, with its median value being $203.5 million (2021).
  • In the last 5 years, Moderna's Long-Term Deferred Tax soared by 108939.39% in 2022 and then plummeted by 9452.7% in 2024.
  • Over the past 4 years, Moderna's Long-Term Deferred Tax (Quarter) stood at $326.0 million in 2021, then skyrocketed by 201.23% to $982.0 million in 2022, then tumbled by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
  • Its Long-Term Deferred Tax was $81.0 million in Q3 2024, compared to $81.0 million in Q2 2024 and $81.0 million in Q1 2024.